RAF1 and melanoma: Solit et al. emphasized the concept that RAF/MAPK signaling is dispensable for the oncogenic activity of NRAS mutant melanomas, and they suggested that a single-agent therapeutic strategy may be insufficient in RAS mutant tumors [96].